摘要
对罗非鱼肠道来源真菌Alternaria tenuissima SCSIO41701大米培养基发酵产物中抑制罗非鱼无乳链球菌和海豚链球菌生长的活性化合物进行研究。结合抗菌活性追踪,采用硅胶柱层析和HPLC等色谱技术对其抗菌活性组分进行分离纯化,并通过1H NMR和13 C NMR波谱技术,以及与文献报道的NMR数据相比较鉴定化合物结构。共分离鉴定了9个化合物,分别是aternariol(1)、aternariol methyl ether(2)、3-hydroxyalternariol 5-O-methylether(3)、(-)-altenuene(4)、(+)-isoaltenuene(5)、altenusin derivative(6)、alternariphent(7)、talaroflavonene(8)、alternarienonic acid B(9)。其中含量最高的化合物1抗菌活性最强,在25μg/disc的浓度下对罗非鱼病原菌无乳链球菌和海豚链球菌均有显著抑制作用,抑菌圈直径均为10 mm,且其MIC值均为12.5μg/mL。这是首次报道化合物1抗罗非鱼链球病病原菌活性。
This study investigated antibacterial compounds from the rice medium of the tilapia intestinal derived fungus Alternaria tenuissima SCSIO41701.The compounds were separated by silica gel column chromatography,HPLC and other chromatographic techniques.The structures of the compounds were identified by 1H NMR,13 C NMR,and comparison with the NMR data of literatures.Totally,nine compounds were isolated from the antibacterial fractions of the tilapia intestines derived fungus Alternaria tenuissma.These compounds were identified as aternariol(1),aternariol methyl ether(2),3-hydroxyalternariol 5-O-methylether(3),(-)-altenuene(4),(+)-isoaltenuene(5),altenusin derivative(6),alternariphent(7),talaroflavonene(8),and alternarienonic acid B(9).Only compound 1 showed obvious inhibition activity against the growths of Streptococcus iniae and S.agalactiae at 25μg/dics with inhibition zones of 10 mm,and its MIC values were 12.5μg/mL.
作者
刘瑶
张晓勇
程霞
梁潇
漆淑华
LIU Yao;ZHANG Xiao-yong;CHENG Xia;LIANG Xiao;QI Shu-hua(Key Laboratory of Tropical Marine Bio-resources and Ecology,South China Sea Insitute of Oceanology,Chinese Academy of Science,Guangzhou 510301,China;Graduate University of the Chinese Academy of Sciences,Beijing 100049,China;Southern Marine Science and Engineering Guangdong Laboratory,Guangzhou 511458,China;South China Agricultural University,Guangzhou 510642,China)
出处
《天然产物研究与开发》
CAS
CSCD
2021年第10期1713-1719,共7页
Natural Product Research and Development
基金
广东省海洋经济发展专项资金(编号粤自然资合[2020]032号)
南方海洋科学与工程广东省实验室(广州)人才团队引进重大专项(GML2019ZD0406)
广东省重点领域研发计划(2020B1111030005)。